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Abstract
Background/Aims
Anti-ganglionic nicotinic acetylcholine receptor (gAChR) antibodies are observed in autoim-
mune diseases, as well as in patients with autoimmune autonomic ganglionopathy. How-
ever, the genetic background of anti-gAChR antibodies is unclear. Here, we investigated
HLA alleles in autoimmune hepatitis (AIH) patients with or without anti-gAChR antibodies.
Methodology/Principal Findings
Genomic DNA from 260 patients with type-1 autoimmune hepatitis (AIH) were genotyped
for HLA-A, B, DRB1, and DQB1 loci. Anti-gAChR antibodies in the sera form AIH patients
were measured using the luciferase immunoprecipitation system, and examined allelic
association in patients with or without anti-gAChR antibodies.
Methodology/ Methods
We detected anti-α3 or -β4 gAChR antibodies in 11.5% (30/260) of patients with AIH.
Among AIH patients there was no significant association between HLA-A, B DQB1 alleles
and the positivity for anti-gAChR antibodies. Whereas the HLA-DRB1*0403 allele showed
a significantly increased frequency in AIH patients with anti-gAChR antibodies compared
with those without anti-gAChR antibodies.
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Conclusions/Significance
The frequency of the HLA-DRB1*0403 allele differed among Japanese patients with AIH
according to the presence or absence of anti-gAChR antibodies. Our findings suggest that
particular HLA class II molecules might control the development of anti-gAChR antibodies
in the autoimmune response to gAChR.
Introduction
Autoimmune autonomic ganglionopathy (AAG) is an acquired channelopathy that is character-
ized by pandysautonomia [1], in which autoantibodies to ganglionic nicotinic acetylcholine
receptors (gAChR) may play a central role [2]. We established the luciferase immunoprecipita-
tion system (LIPS) assay as a new tool to detect anti-gAChR antibodies and demonstrated these
auto-antibodies in AAG [3]. Furthermore, using this established anti-gAchR antibody assay sys-
tem, we reported that a significant proportion of patients with autoimmune diseases were posi-
tive for anti-gAChR antibodies [3]. Anti-gAChR antibodies in the patient’ serum recognize
(alpha and beta subunits) of the ganglionic acetylcholine receptor [4]. The major histocompati-
bility complex (MHC) genes are the best documented genetic risk factors for the development of
autoimmune diseases and could be involved in autoantibody production [5]. This is because of
their expression on antigen-presenting cells, which could favor presentation of autoantigen epi-
topes to T cells, leading to specific help in autoantibody production [6]. For example, an
increased frequency of conservedHLA-DRB1 domain “shared epitopes” has been demonstrated
in rheumatoid arthritis patients with anti-citrullinated peptide antibodies [7]. Similarly, a genetic
predisposition to autoantibody production in autoimmune hepatitis (AIH) has been shown to be
associated withHLA genes [8]. We hypothesized that antibodies against gAChR exist in a subset
of AIH patients with genetic susceptibility factors, includingHLA. We genotyped theHLA-A, B,
DRB1, and DQB1 genes in 260 AIH patients with or without anti-gAChR antibodies and evalu-
ated the association betweenHLA genotype and the production of anti-gAChR antibodies.
Materials and Methods
Study population
Consecutive type-1 AIH patients were initially enrolled in the register of the Japanese National
Hospital Organization (NHO) liver-network study, contributed to medical facilities in Japan,
and prospectively followed since 2009 as a multicenter cohort population [9] All patients satis-
fied the 1999 revised criteria of International Autoimmune Hepatitis Group (IAIHG) diagnosis
of type-1 AIH [10]. Patients were excluded from the study if there was histological evidence of
cholangitis or non-alcoholic steatohepatitis. In addition, patients who were positive for hepati-
tis B virus (HBV)-surface antigen (HBsAg) or hepatitis C virus (HCV)-RNA were excluded.
Patients with other causes of liver disease, such as excess alcohol or drug use, were excluded
based on reviews of their appropriate history and investigations. The control groups included
in this study consisted of 73 healthy controls (HC; mean age, 38.3 ± 11.1 years old, 31 males
and 42 females) and 34 subjects with other neurological diseases with any autonomic symp-
toms (OND; Mean age, 56.3 ± 20.4 years old, 19 males and 15 females). The control group for
HLA-DRB1 genotyping consisted of 120 gender-matched Japanese healthy subjects (6 men and
114 women). The mean ±SD age was 46.0±14.3 years. All of subjects gave their written,
informed consent to participate in the present study. The study was approved by the Ethics
Committee of National Hospital Organization (NHO) central IRB (H26-2111007).
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Variables at study entry
Demographic and other characteristics of the 230 retained patients were recorded in a database
at the initial assessment. Data included sex, age at diagnosis, time of onset of symptoms or
other evidence of liver disease, markers of infection with hepatitis viruses HBV and HCV, alco-
hol intake, coexisting autoimmune diseases, serum levels of ALT, AST, alkaline phosphatase
and bilirubin, platelet count and prothrombin time. Anti-nuclear antibodies (ANA) and anti-
smooth muscle antibodies (ASMA) were measured by indirect immunofluorescence on HEp-2
cells and cut-off titers for positivity were 1:40. Liver tissue from percutaneous biopsy per-
formed at the referring facility was available for the majority of patients at the time of entry
(223/260, 85.8%), but for only a few at the subsequent follow-up examination (8/260, 3.1%).
HLA-A, B, -DRB1 and -DQB1 genotyping
DNA was extracted from the blood sample and subjected to HLA-A, B, -DRB1 and -DQB1ge-
notype determination by WAKFlow HLA typing kit (Wakunaga Pharmaceutical, Osaka,
Japan) based on the reverse sequence-specific oligonucleotide probes method coupled with
xMAP technology designed for use with the Luminex system (Luminex Japan, Tokyo, Japan).
LIPS assay for the detection of autoantibodies to gAChR[3]
Serum antibodies to gAChR were detected by the LIPS assay, as described elsewhere [3]. To
generate luciferase reporters for the gAChR α3 and β4 subunits (termed gAChRα3-GL and
gAChRβ4-GL, respectively) of the human gAChR, full-length human AChR α3 (P32297, Pro-
mega Corporation, Madison, WI, USA) or β4 (P30296, Promega Corporation) was fused to a
Gaussia luciferase (GL) mutant (GL8990). Human embryonic kidney (HEK) 293F cells (Life
Technologies Corportion, Graind Island, NY, USA) were then transfected with the expression
plasmid encoding either gAChRα3-GL or gAChRβ4-GL with FuGENE6 (Promega Corpora-
tion). Two days later, the transfected cells were solubilized with a Tris-based saline containing
1% Triton™ X-100. To detect α3 or β4 gAChR antibodies, 100 μL of the soluble fraction, con-
taining gAChR α3-GL or gAChR β4-GL, was incubated with 15 μL of human serum for 1 hour
at 4°C. Subsequently, the fraction was mixed with 15 μL of protein G-sepharose (GE Health-
care, Little Chalfont, Buckinghamshire, UK), 600 μL phosphate-buffered saline (PBS) with 3%
bovine serum albumin and 0.05% Tween1 20, and incubated for several hours at 4°C. Follow-
ing centrifugation and two washes of PBS containing 0.05% Tween1 20, bioluminescence
activities of the luciferase reporters in protein G-sepharose were measured with a BioLux™ GL
assay kit (New England Biolabs, Ipswich, MA, USA) and a Lumat LB 9507 luminometer
(BERTHOLD TECHNOLOGIES GmbH & Co. KG, Bad Wildbad, Germany); luminometer
output was measured in relative luminescence units (RLU). In order to confirm the accuracy of
the LIPS assay for gAChR antibodies, we used commercially available antibodies to human
gAChR α3 and β4 (H-100 and S-15; Santa Cruz Biotechnology, Inc., Dallas, TX, USA) as posi-
tive controls. Based on anti-gAChRα3 and β4 antibody data from the 73 HCs, cut-off values
were calculated as the mean plus 3 standard deviations (SD) from the mean. In this study, anti-
body levels were expressed as an antibody index (A.I.) that was calculated as follows:
A:I ¼ ½measurement value of the samples erum ðRLUÞ=½the cut  off value ðRLUÞ
The normal value that was established in this study from healthy individuals was<1.0 A.I.
To evaluate the diagnostic accuracy of this assay, we verified the cut-off points for all data
collected in the previous study. Cut-off points calculated sensitivity and specificity, and ROC
curves were obtained. According to the ROC curves, we confirmed the most discriminative
HLA and Anti-Ganglionic Nicotinic Acetylcholine Receptor Antibody
PLOS ONE | DOI:10.1371/journal.pone.0146048 January 25, 2016 3 / 16
cut-off points. At these points, the sensitivity, specificity, and positive and negative predictive
values (PPV and NPV) were calculated. The AUC was 0.849 (95% confidence interval [CI]:
0.786–0.911) for the LIPS assay of the anti-gAChRα3 antibody. With the anti-gAChRα3 anti-
body cut-off point of 1.0, the sensitivity and specificity were 46.9% (95% CI: 33.7–60.6%) and
99.2% (95% CI: 94.8–100.0%), respectively, and the PPV and NPV were 95.8% and 81.8%,
respectively. The AUC was 0.720 (95% CI: 0.632–0.807) for the LIPS assay of the anti-
gAChRβ4 antibody. With the anti-gAChRβ4 antibody cut-off point of 1.0, the sensitivity and
specificity were 14.3% (95% CI: 6.9–27.1%) and 100.0% (95% CI: 96.2–100.0%), respectively.
The PPV and NPV were 100.0% and 74.4%, respectively. This sensitivity and specificity anti-
gAChRα3 antibody in our assay system is similar to the previous reports [11].
Statistics
The distribution of HLA types was compared between patients with or without anti-gAChR
antibodies. The risk/protective effects of carrier status of HLA alleles were evaluated by odds
ratio (OR) obtained by the comparison of frequencies between patients with or without anti-
gAChR antibodies. Comparisons between the 2 groups for phenotype frequencies of each HLA
allele were made, and each p value was corrected (Pc), multiplying by the number of tested
alleles at each considered locus. p values were regarded as significant when they were less than
0.05. Continuous variables were compared using Mann-Whitney tests. All the statistical analy-
ses were performed using the Statistical Analysis System (SAS) and SPSS version 18 software
(SPSS, Chicago, IL, USA).
Results
Demographic data
Table 1 shows the demographic data for the enrolled type-1 AIH patients. The age at diagnosis
ranged from 15 to 88 years (mean, 60.2 ± 12.7 years), which is greater than that in earlier studies
on Caucasian patients, and females predominated. In 45 (17.3%) patients, there was concurrent
symptomatic autoimmune disease, notably, Hashimoto's disease 18; Sjögren's syndrome 13;
Rheumatoid arthritis 13; Basedow disease 2; Primary biliary cirrhosis 1; Systemic lupus erythe-
matosus 1; Multiple sclerosis 1; CREST syndrome 1; Polymyalgia rheumatica 1; Scleroderma 1;
Mixed Connective Tissue Disease 1; Idiopathic Thrombocytopenic Purpura 1. Regarding tests
for autoantibodies, data for SMA were lacking in 2 and for ANA in 1. Of those tested, 232
(89.6%) gave positive tests (titer> 1:40) for ANA and 36 (40.9%) for SMA. Ninety-eight patients
(37.7%) had been treated with prednisolone and 51 (9.6%) with ursodeoxycholic acid alone.
Clinical characteristics of AIH patients with gAChR antibodies
Of the 260 patients with AIH screened, anti-gAChR α3 antibodies were detected in 28 (10.8%)
patients and anti-gAChR β4 antibodies were detected in 18 (6.9%) patients. Mean anti-
gAChRα3 antibodies in HCs and ONDs were 0.305 A.I. and 0.336 A.I., respectively. These lev-
els were significantly lower than anti-gAChRα3 antibodies in AIH samples, with a mean level
of 0.609 A.I. (p< 0.001, Fig 1A). Mean anti-gAChRβ4 levels in HCs were 0.367 A.I. and in
ONDs was 0.302 A.I., which were significantly lower than that in AIH samples (0.506 A.I.,
p = 0.001, Fig 1B). We investigated the correlation between gAChR α3 and β4 antibodies levels
in patients with both antibodies (n = 17). As shown in Fig 2, there was no significant correla-
tion between gAChR α3 and β4 antibodies levels. Also antibodies against particular gAChR
single submit have been demonstrated [12]. Therefore, the cross-reactivity of gAChR antibod-
ies against α3 and β4 subunits seems to be unlikely. Table 2 shows the clinical characteristics of
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Fig 1. A) LIPS for gAChR in the sera from patients with autoimmune hepatitis (AIH) and controls.We
tested the sera from patients with AIH, disease controls (ODC), and healthy controls (HC). a) Anti-gAChRα3
antibodies were detected in 28 samples. The mean anti-gAChRα3 antibody level in the HC was 0.305
antibody index (A.I.), which was significantly lower than in the AIH samples with a mean level of 0.609 A.I.
(p < 0.001).B) Anti-gAChRβ4 antibodies were also detected in patient with AIH. The mean anti-
gAChRβ4 antibody levels in the HC was 0.367 A.I., which was significantly lower than the mean levels of
0.506 A.I. in the AIH samples (p < 0.001).
doi:10.1371/journal.pone.0146048.g001
Table 1. Baseline Characteristics of 260 Japanese AIH Type 1 Patients.
n = 260
Gender (male/female) 29/231
Age at presentaion (years) 60.2±12.7
Other autoimmune diseases 45(17.3%)
Baseline Laboratory Values
AST (IU/L) 450.9±452.9
ALT (IU/L) 500.5±500.1
ALP (IU/L) 463.5±199.2
Total Bilirubin (mg/dl) 3.61±4.89
Albumin (g/dl) 3.83±0.57
IgG (mg/dl) 2431.7±889.7
Platelets (104/μl) 18.8±7.0
ANA + (≧1:40) 232/259(89.6%)
ASMA + (≧1:40) 104/258(40.3%)
Cirrhosis at presentation 40(15.4%)
Received treatment
Steroid alone 98(37.7%)
Steroid + UDCA 94(36.2%)
Steroid + Aza 9(3.5%)
UDCA alone 51(19.6%)
AIH, autoimmune hepatitis; AST, aspartate aminotransferase; ALT, alanine aminotransferase; ALP, alkaline
phosphate; IgG, immunoglobulin G; ANA, anti-nuclear antibody; ASMA, anti-smooth muscle antibody;
UDCA, ursodeoxy cholic acid; Aza, azathioprine. Data are expressed as number (percentage) or mean
±standard deviations.
doi:10.1371/journal.pone.0146048.t001
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Fig 2. Relationship between anti-gAChR α3 and anti- gAChR β4 antibody levels.Calculation of the
correlation between anti-gAChR α3 and anti-gAChR β4 antibody levels in AIH patients with both
autoantibodies (n = 17). Correlation was calculated using Spearman’s Rank Correlation test. There is no
correlation at all (r = -0.04, p = 0.58).
doi:10.1371/journal.pone.0146048.g002
Table 2. Baseline characteristics of AIH patients with or without anti-gAChR Ab (alpha 3).
anti-gAChR alpha 3
positive (n = 28) negative (n = 232) p
Female 22(78.6%) 209(90.1%) 0.073
Age at presentaion (years) 61.4±12.9 60.0±12.8 0.629
Other autoimmune diseases 5(17.9%) 40(17.2%) 0.554
Baseline Laboratory Values
AST (IU/L) 370.8±320.8 460.3±465.5 0.729
ALT (IU/L) 414.6±405.8 510.5±509.8 0.580
ALP (IU/L) 439.3±134.8 466.4±205.5 0.751
Total Bilirubin (mg/dl) 2.70±3.36 3.71±5.04 0.865
Albumin (g/dl) 3.62±0.57 3.85±0.56 0.045
IgG (mg/dl) 2644.4±916.2 2406.9±885.4 0.236
Platelets (104/μl) 15.7±7.5 19.1±6.9 0.005
ANA + (≧1:40) 27(96.4%) 205(88.7%) 0.179
ASMA + (≧1:40) 13(46.4%) 91(39.6%) 0.485
Cirrhosis at presentation 5(17.9%) 35(15.1%) 0.438
Received treatment
Steroid alone 10(35.7%) 88(37.9%) 0.819
Steroid + UDCA 8(28.6%) 86(37.1%) 0.377
Steroid + Aza 1(3.6%) 8(3.4%) 0.647
UDCA alone 7(25.0%) 44(19.0%) 0.447
AIH, autoimmune hepatitis; AST, aspartate aminotransferase; ALT, alanine aminotransferase; ALP, alkaline
phosphate; IgG, immunoglobulin G; ANA, anti-nuclear antibody; ASMA, anti-smooth muscle antibody;
UDCA, ursodeoxy cholic acid; Aza, azathioprine. Data are expressed as number (percentage) or mean
±standard deviations.
doi:10.1371/journal.pone.0146048.t002
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AIH patients with or without gAChR antibodies. The gAChR antibody-positive (ab+) patients
had significantly lower serum albumin levels at the time of registering, as well as lower platelet
counts compared with those of the gAChR antibody-negative (ab–) patients (Tables 2 and 3).
HLA-A, B alleles among AIH patients with anti-gAChR ab
The results of HLA-A and -B loci typing among AIH patients with anti-gAChR antibodies are
summarized in S1–S3 Tables. The frequencies ofHLA-A and -B alleles were not significantly
different between gAChR ab+ and ab−AIH patients.
Frequencies of HLA-DRB1 and DQB1 alleles
As shown in Table 4, gAChR α3 ab+ AIH patients had a higher frequency of the DRB10403
allele than did gAChR α3 ab−patients. Similarly, gAChR β4 ab+ AIH patients had a higher fre-
quency of the DRB10403 allele compared with gAChR β4 ab−patients (Table 5). The frequen-
cies of theHLA-DRB1 0403 allele were significantly increased in AIH patients with anti-
gAChR α3 or β4 antibodies (Table 6). We compared the antibody index (AI) of anti-gAChR
antibodies between AIH patients with or without HLA-DRB1 0403 allele (Fig 3). The levels of
AI for anti-gAChR α3 in patients with 0403 allele (1.06±0.74 A.I) were significantly higher
compared to those without 0403 allele (0.59±0.71 A.I). Similarly, the levels of AI for anti-
Table 3. Baseline characteristics of AIH patients with or without anti-gAChR Ab (beta 4).
anti-gAChR beta 4
positive (n = 18) negative (n = 242) p
Female 15(83.3%) 216(89.3%) 0.324
Age at presentaion (years) 62.2±14.3 60.0±12.6 0.448
Other autoimmune diseases 3(16.7%) 42(17.4%) 0.620
Baseline Laboratory Values
AST (IU/L) 357.7±361.3 457.5±458.6 0.439
ALT (IU/L) 441.3±515.3 504.7±499.9 0.392
ALP (IU/L) 452.5±168.8 464.3±201.5 0.974
Total Bilirubin (mg/dl) 3.04±3.93 3.65±4.96 0.864
Albumin (g/dl) 3.51±0.55 3.85±0.56 0.011
IgG (mg/dl) 2451.5±805.2 2430.3±896.8 0.852
Platelets (104/μl) 15.3±8.9 19.0±6.8 0.011
ANA + (≧1:40) 18(100%) 214(88.8%) 0.128
ASMA + (≧1:40) 8(44.4%) 96(40.0%) 0.711
Cirrhosis at presentation 5(27.8%) 35(14.5%) 0.123
Received treatment
Steroid alone 8(44.4%) 90(37.2%) 0.540
Steroid + UDCA 2(11.1%) 92(38.0%) 0.022
Steroid + Aza 1(5.6%) 8(3.3%) 0.481
UDCA alone 5(27.8%) 46(19.0%) 0.264
AIH, autoimmune hepatitis; AST, aspartate aminotransferase; ALT, alanine aminotransferase; ALP, alkaline
phosphate; IgG, immunoglobulin G; ANA, anti-nuclear antibody; ASMA, anti-smooth muscle antibody;
UDCA, ursodeoxy cholic acid; Aza, azathioprine. Data are expressed as number (percentage) or mean
±standard deviations.
doi:10.1371/journal.pone.0146048.t003
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gAChR β4 antibodies in patients with 0403 allele (0.76±0.33 A.I) were significantly higher
compared to those without 0403 allele (0.50±0.32 A.I). Finally, theHLA-DRB1 alleles distribu-
tions in type 1 AIH were compared with gender-matched Japanese healthy subjects.
HLA-DRB1 0405 allele, not DRB1 0403, had been shown to be a genetic factor in Japanese
patients with type-1 AIH [13]. In consistent with the previous report [13], theHLA-DRB1
0405 alleles were associated with type I AIH, whereas, no significant difference in the fre-
quency of DRB1 0403 was present between AIH patients and healthy subjects (Table 7).
Therefore, the increased frequencies of AIH susceptibleHLA-DRB1 allele may not linked to
the production of anti-gAChR antibody, and a passible association between DRB1 0403 and
anti-gAchR Ab was suggested.
The frequency of theHLA-DQB1 allele was not significantly different between gAChR ab+
and gAChR ab−AIH patients (Table 8).
Table 4. HLA-DRB1 alleles of AIH patients with or without anti-gAChR Ab (alpha 3).
anti-gAChR alpha 3
HLA alleles anti-gAChR alpha 3
positive (n = 28) negative (n = 232) OR(95%CI) Pc
HLA-DRB1
DRB1*01:01 3(10.7%) 11(4.7%) 2.411(0.630–9.225) ns(5.020)
DRB1*03:01 0 1(0.4%) ns
DRB1*04:01 4(14.3%) 12(5.2%) 3.056(0.913–10.221) ns(1.567)
DRB1*04:03 4(14.3%) 4(1.7%) 9.500(2.232–40.432) 0.007
DRB1*04:05 13(46.4%) 142(61.2%) 0.549(0.250–1.208) ns(3.569)
DRB1*04:06 2(7.1%) 6(2.6%) 2.897(0.556–15.102) ns(5.055)
DRB1*04:07 0 2(0.9) ns
DRB1*04:10 0 7(3.0%) ns
DRB1*07:01 0 2(0.9%) ns
DRB1*08:02 2(7.1%) 23(9.9%) 0.699(0.156–3.137) ns(17.239)
DRB1*08:03 6(21.4%) 34(14.7%) 1.588(0.600–4.203) ns(9.397)
DRB1*09:01 9(32.1%) 49(21.1%) 1.769(0.754–4.153) ns(5.014)
DRB1*10:01 0 4(1.7%) ns
DRB1*11:01 1(3.6%) 7(3.0%) 1.190(0.141–10.048) ns(23.559)
DRB1*12:01 2(7.1%) 14(6.0%) 1.198(0.258–5.567) ns(22.077)
DRB1*12:02 0 9(3.9%) ns
DRB1*13:01 0 2(0.9%) ns
DRB1*13:02 3(10.7%) 13(5.6%) 2.022(0.539–7.581) ns(7.770)
DRB1*14:01 0 3(1.3%) ns
DRB1*14:03 0 3(1.3%) ns
DRB1*14:05 0 9(3.9%) ns
DRB1*14:06 0 5(2.2%) ns
DRB1*14:07 1(3.6%) 0 ns
DRB1*14:54 0 9(3.9%) ns
DRB1*15:01 2(7.1%) 27(11.6%) 0.584(0.131–2.600) ns(12.835)
DRB1*15:02 3(10.7%) 40(17.2%) 0.576(0.166–2.001) ns(10.256)
DRB1*16:02 1(3.6%) 3(1.3%) 2.827(0.284–28.143) ns(9.580)
Associations were tested by Fisher’s extract test using 2×2 contingency tables. Odds ratio (and its 95% conﬁdence intervals) for the carrier of HLA-DRB1
were calculated in two groups with or without anti-gAchR. Corrected p-valules (Pc values) were calculated by Bonferroni's procedure.
doi:10.1371/journal.pone.0146048.t004
HLA and Anti-Ganglionic Nicotinic Acetylcholine Receptor Antibody
PLOS ONE | DOI:10.1371/journal.pone.0146048 January 25, 2016 8 / 16
Discussion
Although it is accepted that AAG and other autoimmune diseases can coexist because of a
background of autoimmunity, few reports have examined anti-gAChR antibodies in autoim-
mune diseases [14]. We established the LIPS assay as a new tool to detect autoantibodies
against gAChR [3]. Using this assay, we demonstrated that a significant number of AIH
patients have this autoantibody. This study comprised 260 Japanese patients with AIH, who
were carefully selected according to the diagnostic criteria for type 1 AIH. We performed
molecular genetic analysis of HLA genes in these patients, and compared the findings against
anti-gAChR antibody status. We found that anti-gAChR antibody positivity was associated
with the HLA-DRB10403 allele. Therefore, it is possible that the HLA-DRB1 gene controls
anti-gACHR antibody production and that this production is modulated by particular
Table 5. HLA-DRB1 alleles of AIH patients with or without anti-gAChR Ab (beta 4).
anti-gAChR beta 4
HLA alleles anti-gAChR beta 4
positive (n = 18) negative (n = 242) OR(95%CI) Pc
HLA-DRB1
DRB1*01:01 1(5.6%) 13(5.4%) 1.036(0.128–8.401) ns(26.283)
DRB1*03:01 0 1(0.4%) ns
DRB1*04:01 2(11.1%) 14(5.8%) 2.036(0.425–9.745) ns(9.837)
DRB1*04:03 3(16.7%) 5(2.1%) 9.480(2.066–43.497) 0.015
DRB1*04:05 6(33.3%) 149(61.6%) 0.312(0.113–0.860) ns(0.499)
DRB1*04:06 2(11.1%) 6(2.5%) 4.917(0.918–26.341) ns(1.101)
DRB1*04:07 0 2(0.8%) ns
DRB1*04:10 0 7(2.9%) ns
DRB1*07:01 0 2(0.8%) ns
DRB1*08:02 1(5.6%) 24(9.9%) 0.534(0.068–4.194) ns(14.709)
DRB1*08:03 4(22.2%) 36(14.9%) 1.635(0.509–5.248) ns(10.925)
DRB1*09:01 5(27.8%) 53(21.9%) 1.372(0.468–4.020) ns(15.211)
DRB1*10:01 0 4(1.7%) ns
DRB1*11:01 1(5.6%) 7(2.9%) 1.975(0.229–16.993) ns(14.254)
DRB1*12:01 2(11.1%) 14(5.8%) 2.036(0.425–9.745) ns(9.837)
DRB1*12:02 0 9(3.7%) ns
DRB1*13:01 0 2(0.8%) ns
DRB1*13:02 2(11.1%) 14(5.8%) 2.036(0.425–9.745) ns(9.837)
DRB1*14:01 1(5.6%) 2(0.8%) 7.059(0.609–81.828) ns(1.887)
DRB1*14:03 0 3(1.2%) ns
DRB1*14:05 0 9(3.7%) ns
DRB1*14:06 0 5(2.1%) ns
DRB1*14:07 1(5.6%) 0 ns
DRB1*14:54 0 9(3.7%) ns
DRB1*15:01 3(16.7%) 26(10.7%) 1.662(0.451–6.125) ns(11.913)
DRB1*15:02 1(5.6%) 42(17.4%) 0.280(0.036–2.163) ns(5.227)
DRB1*16:02 1(5.6%) 3(1.2%) 4.686(0.462–47.497) ns(4.082)
Associations were tested by Fisher’s extract test using 2×2 contingency tables. Odds ratio (and its 95% conﬁdence intervals) for the carrier of HLA-DRB1
were calculated in two groups with or without anti-gAchR. Corrected p-valules (Pc values) were calculated by Bonferroni's procedure.
doi:10.1371/journal.pone.0146048.t005
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HLA-DRB1 alleles. Type-1 AIH is characterized by the presence of anti-smooth muscle antigen
(SMA) directed against smooth muscle actin [15]. Whereas anti-gAChR antibodies specifically
recognize neuronal α or β subunits of acetylcholine receptor. Therefore, the cross-reactivity of
anti-gAChR antibodies against liver antigens such as smooth muscle antigen seems to be insig-
nificant. Furthermore, the associations between anti-SMA antibodies and HLA-B8 or DR3
alleles were reported [16]. Therefore genetic predisposition of type-1 AIH specific autoanti-
body (anti-SMA antibody) may not affect the production of anti-gAChR antibodies. Type 2
and type 3 autoimmune hepatitis are rare disorders characterized by antibodies against liver-
kidney microsome 1 (LKM1) and soluble liver antigens (SLA) [17,18]. Genetic predispositions
including HLA for these autoantibodies (anti-SMA. LKM1 and SLA) were shown to be differ-
ent [19]. We could not recruit these different subtypes of AIH patients in this study. We
focused on the type 1 AIH rather than heterogeneous AIH subtypes with differential genetic
predispositions and autoantibody profiles.
Table 6. HLA-DRB1 alleles of AIH patients with or without anti-gAChR Ab (beta 4).
HLA alleles anti-gAChR alpha 3 or beta 4
positive (n = 30) negative (n = 230) OR(95%CI) Pc
HLA-DRB1
DRB1*01:01 3(10.0%) 11(4.8%) 2.212(0.581–8.429) ns(6.311)
DRB1*03:01 0 1(0.4%) ns
DRB1*04:01 5(16.7%) 11(4.8%) 3.982(1.280–12.391) ns(0.293)
DRB1*04:03 4(13.3%) 4(1.7%) 8.692(2.051–36.839) 0.015
DRB1*04:05 13(43.3%) 142(61.7%) 0.474(0.220–1.023) ns(1.439)
DRB1*04:06 2(6.7%) 6(2.6%) 2.667(0.513–13.855) ns(6.104)
DRB1*04:07 0 2(0.9%) ns
DRB1*04:10 0 7(3.0%) ns
DRB1*07:01 0 2(0.9%) ns
DRB1*08:02 2(6.7%) 23(10.0%) 0.643(0.144–2.875) ns(15.126)
DRB1*08:03 7(23.3%) 33(14.3%) 1.817(0.722–4.572) ns(5.387)
DRB1*09:01 9(30.0%) 49(21.3%) 1.583(0.682–3.675) ns(7.612)
DRB1*10:01 0 4(1.7%) ns
DRB1*11:01 1(3.3%) 7(3.0%) 1.099(0.130–9.250) ns(25.140)
DRB1*12:01 2(6.7%) 14(6.1%) 1.102(0.238–5.105) ns(24.330)
DRB1*12:02 0 9(3.9%) ns
DRB1*13:01 0 2(0.9%) ns
DRB1*13:02 3(10.0%) 13(5.7%) 1.855(0.497–6.926) ns(9.486)
DRB1*14:01 1(3.3%) 2(0.9%) 3.931(0.346–44.713) ns(6.336)
DRB1*14:03 0 3(1.3%) ns
DRB1*14:05 0 9(3.9%) ns
DRB1*14:06 0 5(2.2%) ns
DRB1*14:07 1(3.3%) 0 ns
DRB1*14:54 0 9(3.9%) ns
DRB1*15:01 3(10.0%) 26(11.3%) 0.872(0.247–3.076) ns(22.436)
DRB1*15:02 3(10.0%) 40(17.4%) 0.528(0.153–1.825) ns(8.246)
DRB1*16:02 1(3.3%) 3(1.3%) 2.609(0.263–25.919) ns(10.685)
Associations were tested by Fisher’s extract test using 2×2 contingency tables. Odds ratio (and its 95% conﬁdence intervals) for the carrier of HLA-DRB1
were calculated in two groups with or without anti-gAchR. Corrected p-valules (Pc values) were calculated by Bonferroni's procedure.
doi:10.1371/journal.pone.0146048.t006
HLA and Anti-Ganglionic Nicotinic Acetylcholine Receptor Antibody
PLOS ONE | DOI:10.1371/journal.pone.0146048 January 25, 2016 10 / 16
HLA-DRB1 is one of the best known polymorphic loci in the human genome, with more
than 1700 alleles [20].HLA-DRB1 alleles contribute to the development of autoimmune dis-
eases as well as the production of autoantibodies [21]. For the last two decades, scientists have
been investigating the relationship between HLA-DRB1 alleles and autoantibodies [5]. An
important discovery was that shared epitope-encoding DRB1 alleles have been linked to high
levels of anti-citrullinated peptide (CCP) antibody in rheumatoid arthritis [22]. Shared epi-
tope-encoding alleles such as DRB104:01 and 04:04 that confer rheumatoid arthritis suscepti-
bility are more common in different ethnic populations [23]. Epitope recognition via
restriction by the MHC is required for effective T cell help [24]. Documented associations
between anti-CCP antibodies and particular HLA class II alleles are likely to reflect presenta-
tion of selected T cell determinants. It has been proposed that several positions of the DRB1
molecule independently play a role in antigen presentation according to the nature of the anti-
gen [25].
At present, there is no mechanistic explanation for the association of particularHLA alleles
with anti-gAChR antibody responses. Although linkage disequilibrium with non-HLA alleles
cannot be ruled out, it is possible that different HLA class II alleles share relevant amino acid
residues in the hypervariable regions, which are considered important for antigen presentation
to T cells [26]. Peptide motifs for MHC class II binding and T cell receptors for antigen recog-
nition are presumed to be crucial for immunodominant self-peptides and activation of auto-
reactive T cells [27]. Recent studies of theHLA class II region suggested several candidate
amino acids in the hypervariable regions of theHLA-DRB1 alleles that are predicted to map to
the floor of the peptide-binding groove of class II MHC molecules [28]. They could function by
presenting antigenic peptides to lymphocytes to initiate anti-gAChR autoimmune responses.
We speculate that anti-gAchR antibody production requires efficient help to B cells, which
could be provided by DRB10403-restricted T helper cells recognizing gAChR determinants.
This explanation may account for the differential DRB1 allele association with anti-gAChR
Fig 3. LIPS for gAChR in the sera from AIH patients with or without HLA-DRB1 *0403 allele.We tested
the sera from AIH patients with or without HLA-DRB1 *0403 allele. The mean anti-gAChR α3 antibody level
in patient with *0403 allele was 1.06 antibody index (AI), which was significantly higher than in those without
*0403 allele with a mean level of 0.59 A.I. (p = 0.043). The mean anti-gAChR β4 antibody level in patients
with *0403 allele was 0.76A.I, which was significantly higher than in the mean level of 0.50A.I. in those
without *0403 allele (p = 0.010).
doi:10.1371/journal.pone.0146048.g003
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antibodies, but does not give any clue as to the reason for the necessary presence of anti-
gAChR antibodies.
DRB10403 and 0406 were positively associated with anti-gAChR antibodies, whereas
DRB10405 was negatively associated in this study. The DRB10403 and DRB10406 alleles
share a Glu amino acid at position 74 [29], whereas the DRB10405 allele has Ala at this posi-
tion [23]; this might imply a role for Glu at position 74 in the development of anti-gAChR anti-
bodies. We suggest a mechanism by which different HLA class II molecules preferentially
affect gAChR-specific T helper responses, thereby controlling diversification of the autoanti-
body response. This hypothesis could be tested by examining the specificity and HLA restric-
tion of anti-gAChR antibodies in patients with other autoimmune diseases.
This study has limitations. Most notably, we did not examine clinical manifestations charac-
teristic of AAG in our AIH patients. Clinical investigations are necessary to confirm the rela-
tionship between gAChR antibody positivity and autonomic symptoms. Additionally, it was
Table 7. HLA-DRB1 carrier status in patients with AIH and Healthy controls.
HLA alleles Healthy control AIH
n = 120 n = 260 OR(95%CI) pc
HLA-DRB1
DRB1*01:01 12(10.0%) 14(5.4%) 0.512(0.229–1.144) ns(2.636)
DRB1*03:01 1(0.8%) 1(0.4%) 0.459(0.028–7.408) ns(14.376)
DRB1*04:01 2(1.7%) 16(6.2%) 3.869(0.875–17.103) ns(1.502)
DRB1*04:03 1(0.8%) 8(3.1%) 3.778(0.467–30.551) ns(4.486)
DRB1*04:05 39(32.5%) 155(59.6%) 3.066(1.945–4.834) p<0.00001
DRB1*04:06 9(7.5%) 8(3.1%) 0.392(0.147–1.041) ns(1.418)
DRB1*04:07 0 2(0.8%) ns
DRB1*04:10 7(5.8%) 7(2.7%) 0.447(0.153–1.303) ns(3.068)
DRB1*07:01 2(1.7%) 2(0.8%) 0.457(0.064–3.286) ns(10.155)
DRB1*08:02 4(3.3%) 25(9.6%) 3.085(1.049–9.072) ns(0.865)
DRB1*08:03 18(15.0%) 40(15.4%) 1.030(0.563–1.884) ns(24.916)
DRB1*09:01 34(28.3%) 58(22.3%) 0.726(0.444–1.189) ns(5.466)
DRB1*10:01 1(0.8%) 4(1.5%) 1.859(0.206–16.816) ns(13.373)
DRB1*11:01 4(3.3%) 8(3.1%) 0.921(0.272–3.119) ns(15.050)
DRB1*12:01 8(6.7%) 16(6.2%) 0.918(0.382–2.208) ns(22.910)
DRB1*12:02 4(3.3%) 9(3.5%) 1.040(0.314–3.446) ns(16.393)
DRB1*13:01 0 2(0.8%) ns
DRB1*13:02 24(20.0%) 16(6.2%) 0.262(0.134–0.515) 0.001
DRB1*14:01 0 3(1.2%) ns
DRB1*14:03 4(3.3%) 3(1.2%) 0.339(0.075–1.537) ns(3.924)
DRB1*14:05 2(1.7%) 9(3.5%) 2.116(0.450–9.945) ns(7.292)
DRB1*14:06 3(2.5%) 5(1.9%) 0.765(0.180–3.253) ns(13.199)
DRB1*14:07 0 1(0.4%) ns
DRB1*14:54 5(4.2%) 9(3.5%) 0.825(0.270–2.516) ns(12.635)
DRB1*15:01 15(12.5%) 29(11.2%) 0.879(0.452–1.708) ns(18.982)
DRB1*15:02 30(25.0%) 43(16.5%) 0.594(0.351–1.007) ns(1.394)
DRB1*16:02 1(0.8%) 4(1.5%) 1.859(0.206–16.816) ns(15.525)
Associations were tested by Fisher’s extract test using 2×2 contingency tables. Odds ratio (and its 95% conﬁdence intervals) for the carrier of HLA-DRB1
were calculated in two groups AIH and Healthy controls. Corrected p-valules (pc values) were calculated by Bonferroni's procedure.
doi:10.1371/journal.pone.0146048.t007
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difficult to perform a replication study due to the very low prevalence of type-1 autoimmune
hepatitis and limited numbers of enrolled patients. In this study, we strictly enrolled type-1
AIH patients according to the international diagnostic criteria to maximize diagnostic specific-
ity. Therefore, we could not reserve sufficient sample size, and the possibility of underpowered
study cannot be denied. Additionally, it was difficult to perform a replication study due to the
very low prevalence AIH.
In conclusion, we have presented evidence that an autoimmune response to gAChR is influ-
enced by different HLA-DRB1 alleles in Japanese patients with AIH. We suggest a mechanism
by which different HLA class II molecules might preferentially affect the gAChR-specific T cell
response, controlling diversification of the autoantibody response. This hypothesis should be
further tested by examining the HLA restriction of anti-gAChR antibodies in patients with
autoimmune diseases. Proof awaits the development of an immunodominant epitope of anti-
gAChR antibodies and antigenic motifs for MHC class II binding.
Table 8. HLA-DQB1 alleles of AIH patients with or without anti-gAChR Ab.
anti-gAChR alpha 3
HLA alleles anti-gAChR alpha 3
positive (n = 28) negative (n = 232) OR(95%CI) Pc
HLA-DQB1
DQB1*03:01 7(25.9%) 50(21.6%) 1.274(0.510–3.184) ns(6.640)
DQB1*03:02 6(22.2%) 25(10.8%) 2.366(0.872–6.416) ns(0.912)
DQB1*03:03 7(25.9%) 51(22.0%) 1.242(0.497–3.102) ns(7.060)
DQB1*04:01 9(33.3%) 71(30.6%) 1.134(0.486–2.646) ns(8.485)
DQB1*04:02 6(22.2%) 80(34.5%) 0.543(0.211–1.399) ns(2.205)
DQB1*05:01 3(11.1%) 15(6.5%) 1.808(0.488–6.698) ns(4.059)
DQB1*05:02 2(7.4%) 10(4.3%) 1.776(0.368–8.566) ns(5.156)
DQB1*05:03 0 14(6.0%) ns
DQB1*06:01 8(29.6%) 73(31.5%) 0.917(0.384–2.192) ns(9.302)
DQB1*06:02 2(7.4%) 24(10.3%) 0.693(0.155–3.110) ns(6.938)
DQB1*06:04 3(11.1%) 12(5.2%) 2.292(0.604–8.695) ns(2.323)
anti-gAChR beta 4
HLA alleles anti-gAChR beta 4
positive (n = 18) negative (n = 242) OR(95%CI) Pc
HLA-DQB1
DQB1*03:01 5(27.8%) 52(21.6%) 1.398(0.477–4.100) ns(5.942)
DQB1*03:02 5(27.8%) 26(10.8%) 3.180(1.049–9.639) ns(0.354)
DQB1*03:03 4(22.2%) 54(22.4%) 0.989(0.313–3.130) ns(10.841)
DQB1*04:01 3(16.7%) 77(32.0%) 0.426(0.120–1.515) ns(1.934)
DQB1*04:02 5(27.8%) 81(33.6%) 0.760(0.262–2.205) ns(6.735)
DQB1*05:01 1(5.6%) 17(7.1%) 0.775(0.097–6.181) ns(8.904)
DQB1*05:02 3(16.7%) 9(3.7%) 5.156(1.262–21.056) ns(0.130)
DQB1*05:03 0 14(5.8%) ns
DQB1*06:01 4(22.2%) 77(32.0%) 0.609(0.194–1.910) ns(4.295)
DQB1*06:02 3(16.7%) 23(9.5%) 1.896(0.510–7.039) ns(3.652)
DQB1*06:04 2(11.1%) 13(5.4%) 2.192(0.455–10.565) ns(3.482)
Associations were tested by Fisher’s extract test using 2×2 contingency tables. Odds ratio (and its 95% conﬁdence intervals) for the carrier of HLA-DQB1
were calculated in two groups with or without anti-gAchR. Corrected p-valules (Pc values) were calculated by Bonferroni's procedure.
doi:10.1371/journal.pone.0146048.t008
HLA and Anti-Ganglionic Nicotinic Acetylcholine Receptor Antibody
PLOS ONE | DOI:10.1371/journal.pone.0146048 January 25, 2016 13 / 16
Supporting Information
S1 Table. HLA-A alleles of AIH patients with or without anti-gAChR Ab.
(TIF)
S2 Table. HLA-B alleles of AIH patients with or without anti-gAChR Ab (alpha 3).
(TIF)
S3 Table. HLA-B alleles of AIH patients with or without anti-gAChR Ab (beta 4).
(TIF)
Acknowledgments
This work was supported by a grant from the National Hospital Organization.
This study could not have been accomplished without the effective and dedicated participa-
tion of each of the following contributors: Hiroshi Kamitsukasa (NHO Tokyo National Hospi-
tal), Yoko Nakamura (NHO Sagamihara National Hospital), Hajime Ohta (NHO Kanazawa
Medical Center), Masaaki Shimada (NHO Nagoya Medical Center), Hironao Takahashi (NHO
Higashi Nagoya National Hospital), Eiji Mita (Osaka National Hospital), Taizo Hijioka (NHO
Osaka Minami Medical Center), Yabuuchi Iwao (NHOMinami Wakayama Medical Center),
Haruhiro Yamashita (NHO Okayama Medical Center), Hiroshi Kouno (NHO Kure Medical
Center), Noriaki Naeshiro (NHO Higashihiroshima Medical Center), Makoto Nakamuta
(NHO Kyushu Medical Center), Keisuke Ario (NHO Ureshino Medical Center), Toyokichi
Muro (NHO Oita Medical Center), Hironori Sakai (NHO Beppu Medical Center), Kazuhiro
Sugi (NHO Kumamoto Medical Center), Hideo Nishimura (NHO Asahikawa Medical Center),
Kaname Yoshizawa (NHO Shinshu Ueda Medical Center), Takeaki Sato (NHO Kokura Medi-
cal Center), Atsushi Naganuma (NHO Takasaki General Medical Center), Tatsuji Komatsu
(NHO Yokohama Medical Center), Yukio Oohara (NHO Hokkaido Medical Center), Fujio
Makita (NHO Nishigunma National Hospital), Minoru Tomizawa (NHO Shimoshizu
National Hospital), Masahiro Kikuchi (NHO Tokyo Medical Center)
Author Contributions
Conceived and designed the experiments: KM HF A. Kawakami HY HM S. Nakane. Performed
the experiments: YM OH AMMY. Analyzed the data: YM KMOH S. Nakane. Contributed
reagents/materials/analysis tools: A. Komori MN SH S. Nagaoka SA. Wrote the paper: YM KM
HFMY S. Nakane.
References
1. Vernino S, Low PA, Fealey RD, Stewart JD, Farrugia G, Lennon VA. Autoantibodies to ganglionic ace-
tylcholine receptors in autoimmune autonomic neuropathies. N Engl J Med. 2000; 343: 847–55. PMID:
10995864
2. Wang Z, Low PA, Jordan J, Freeman R, Gibbons CH, Schroeder C, et al. Autoimmune autonomic
ganglionopathy: IgG effects on ganglionic acetylcholine receptor current. Neurology. 2007; 68: 1917–
21. PMID: 17536048
3. Nakane S, Higuchi O, Koga M, Kanda T, Murata K, Suzuki T, et al. Clinical features of autoimmune
autonomic ganglionopathy and the detection of subunit-specific autoantibodies to the ganglionic acetyl-
choline receptor in Japanese patients. PLoS One. 2015; 10: e0118312. doi: 10.1371/journal.pone.
0118312 PMID: 25790156
4. Skok MV, Voitenko LP, Voitenko SV, Lykhmus EY, Kalashnik EN, Litvin TI, et al. Alpha subunit compo-
sition of nicotinic acetylcholine receptors in the rat autonomic ganglia neurons as determined with sub-
unit-specific anti-alpha(181–192) peptide antibodies. Neuroscience. 1999; 93:1427–36. PMID:
10501468
HLA and Anti-Ganglionic Nicotinic Acetylcholine Receptor Antibody
PLOS ONE | DOI:10.1371/journal.pone.0146048 January 25, 2016 14 / 16
5. Reveille JD. The genetic basis of autoantibody production. Autoimmun Rev. 2006; 5: 389–98. PMID:
16890892
6. Wucherpfennig KW, Strominger JL. Selective binding of self peptides to disease-associated major
histocompatibility complex (MHC) molecules: a mechanism for MHC-linked susceptibility to human
autoimmune diseases. J Exp Med. 1995; 181: 1597–601. PMID: 7722439
7. Klareskog L, Stolt P, Lundberg K, Källberg H, Bengtsson C, Grunewald J, et al. A new model for an eti-
ology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reac-
tions to autoantigens modified by citrullination. Arthritis Rheum. 2006; 54: 38–46. PMID: 16385494
8. Oliveira LC, Porta G, Marin ML, Bittencourt PL, Kalil J, Goldberg AC. Autoimmune hepatitis, HLA and
extended haplotypes. Autoimmun Rev. 2011; 10: 189–93. doi: 10.1016/j.autrev.2010.09.024 PMID:
20933106
9. Migita K, Watanabe Y, Jiuchi Y, Nakamura Y, Saito A, Yagura M, et al. Hepatocellular carcinoma and
survival in patients with autoimmune hepatitis (Japanese National Hospital Organization-autoimmune
hepatitis prospective study). Liver Int. 2012; 32: 837–44. doi: 10.1111/j.1478-3231.2011.02734.x
PMID: 22221966
10. Alvarez F, Berg PA, Bianchi FB, Bianchi L, Burroughs AK, Cancado EL, et al. International Autoimmune
Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol. 1999; 31:
929–38. PMID: 10580593
11. Wang Z, Low PA, Jordan J, Freeman R, Gibbons CH, Schroeder C, et al. Autoimmune autonomic
ganglionopathy: IgG effects on ganglionic acetylcholine receptor current. Neurology. 2007; 68: 1917–
21. PMID: 17536048
12. Vernino S. Neuronal acetylcholine receptor autoimmunity. Ann N Y Acad Sci. 2008; 1132: 124–8. doi:
10.1196/annals.1405.011 PMID: 18567861
13. Umemura T, Katsuyama Y, Yoshizawa K, Kimura T, Joshita S, Komatsu M, et al. Human leukocyte
antigen class II haplotypes affect clinical characteristics and progression of type 1 autoimmune hepati-
tis in Japan. PLoS One. 2014; 9:e100565. doi: 10.1371/journal.pone.0100565 PMID: 24956105
14. Winston N, Vernino S. Recent advances in autoimmune autonomic ganglionopathy. Curr Opin Neurol.
2010; 23: 514–8. doi: 10.1097/WCO.0b013e32833d4c7f PMID: 20634694
15. Strassburg CP, Manns MP. Autoantibodies and autoantigens in autoimmune hepatitis. Semin Liver
Dis. 2002; 22: 339–52. PMID: 12447706
16. Czaja AJ, Cassani F, Cataleta M, Valentini P, Bianchi FB. Frequency and significance of antibodies to
actin in type 1 autoimmune hepatitis. Hepatology. 1996; 24: 1068–73. PMID: 8903377
17. Manns MP, Griffin KJ, Sullivan KF, Johnson EF. LKM-1 autoantibodies recognize a short linear
sequence in P450IID6, a cytochrome P-450 monooxygenase. J Clin Invest. 1991; 88: 1370–8. PMID:
1717511
18. Wies I, Brunner S, Henninger J, Herkel J, Kanzler S, Meyer zum Büschenfelde KH, et al. Identification
of target antigen for SLA/LP autoantibodies in autoimmune hepatitis. Lancet. 2000; 355: 1510–5.
PMID: 10801173
19. Bittencourt PL, Goldberg AC, Cançado EL, Porta G, Carrilho FJ, Farias AQ, et al. Genetic heterogene-
ity in susceptibility to autoimmune hepatitis types 1 and 2. Am J Gastroenterol. 1999; 94: 1906–13.
PMID: 10406258
20. Caillat-Zucman S. Molecular mechanisms of HLA association with autoimmune diseases. Tissue Anti-
gens. 2009; 73: 1–8. doi: 10.1111/j.1399-0039.2008.01167.x PMID: 19017300
21. Lie BA, Thorsby E. Several genes in the extended humanMHC contribute to predisposition to autoim-
mune diseases. Curr Opin Immunol. 2005; 17: 526–31. PMID: 16054351
22. Holoshitz J. The rheumatoid arthritis HLA-DRB1 shared epitope. Curr Opin Rheumatol. 2010; 22: 293–
8. doi: 10.1097/BOR.0b013e328336ba63 PMID: 20061955
23. Gonzalez-Gay MA, Garcia-Porrua C, Hajeer AH. Influence of human leukocyte antigen-DRB1 on the
susceptibility and severity of rheumatoid arthritis. Semin Arthritis Rheum. 2002; 31: 355–60. PMID:
12077707
24. Weyand CM, Goronzy JJ. HLA polymorphisms and T cells in rheumatoid arthritis. Int Rev Immunol.
1999; 18: 37–59. PMID: 10614738
25. Rodríguez-Fernández JL. Antigen presentation by dendritic cells in rheumatoid arthritis. Curr Top Med
Chem. 2013; 13: 712–9. PMID: 23574520
26. Zanelli E, Krco CJ, Baisch JM, Cheng S, David CS. Immune response of HLA-DQ8 transgenic mice to
peptides from the third hypervariable region of HLA-DRB1 correlates with predisposition to rheumatoid
arthritis. Proc Natl Acad Sci U S A. 1996; 93: 1814–9. PMID: 8700841
HLA and Anti-Ganglionic Nicotinic Acetylcholine Receptor Antibody
PLOS ONE | DOI:10.1371/journal.pone.0146048 January 25, 2016 15 / 16
27. Goronzy JJ, Weyand CM. Interplay of T lymphocytes and HLA-DRmolecules in rheumatoid arthritis.
Curr Opin Rheumatol. 1993; 5: 169–77. PMID: 8452767
28. LiaoWW, Arthur JW. Predicting peptide binding to Major Histocompatibility Complex molecules. Auto-
immun Rev. 2011; 10: 469–73. doi: 10.1016/j.autrev.2011.02.003 PMID: 21333759
29. Moraes ME, Fernandez-Vina M, Lazaro A, Diaz LA, Filho GH, Friedman H, et al. An epitope in the third
hypervariable region of the DRB1 gene is involved in the susceptibility to endemic pemphigus foliaceus
(fogo selvagem) in three different Brazilian populations. Tissue Antigens. 1997; 49: 35–40. PMID:
9027963
HLA and Anti-Ganglionic Nicotinic Acetylcholine Receptor Antibody
PLOS ONE | DOI:10.1371/journal.pone.0146048 January 25, 2016 16 / 16
